Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

doi:10.1016/j.vaccine.2020.06.058

Comment

. 2020 Jul 22;38(34):5396-5397.

doi: 10.1016/j.vaccine.2020.06.058. Epub 2020 Jun 23.

Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

Wolfram Henn¹

Affiliations

PMID: 32600909
PMCID: PMC7309831
DOI: 10.1016/j.vaccine.2020.06.058

Comment

Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

Wolfram Henn. Vaccine. 2020.

. 2020 Jul 22;38(34):5396-5397.

doi: 10.1016/j.vaccine.2020.06.058. Epub 2020 Jun 23.

Author

Wolfram Henn¹

Affiliation

¹ Institute of Human Genetics, Saarland University, University Clinic Bldg. 68, 66421 Homburg-Saar, Germany. Electronic address: wolfram.henn@uks.eu.

PMID: 32600909
PMCID: PMC7309831
DOI: 10.1016/j.vaccine.2020.06.058

No abstract available

Keywords: Ethics; Health policy; SARS-CoV-2 vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Comment on

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Zhou F, et al. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Lancet. 2020. PMID: 32171076 Free PMC article.

Cited by

Willingness to receive future COVID-19 vaccines following the COVID-19 epidemic in Shanghai, China.
Zhou Y, Zhang J, Wu W, Liang M, Wu QS. Zhou Y, et al. BMC Public Health. 2021 Jun 9;21(1):1103. doi: 10.1186/s12889-021-11174-0. BMC Public Health. 2021. PMID: 34107930 Free PMC article.
Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.
Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, Sawaengdee W, Phumiamorn S, Sapsutthipas S, Sangsupawanich P, Chusri S, Pinpathomrat N. Intapiboon P, et al. Vaccines (Basel). 2021 Nov 23;9(12):1375. doi: 10.3390/vaccines9121375. Vaccines (Basel). 2021. PMID: 34960122 Free PMC article.
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
Kanokudom S, Assawakosri S, Suntronwong N, Chansaenroj J, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Yorsaeng R, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Mongkolsapaya J, Sudhinaraset N, Wanlapakorn N, Honsawek S, Poovorawan Y. Kanokudom S, et al. Vaccine. 2022 Sep 16;40(39):5657-5663. doi: 10.1016/j.vaccine.2022.08.033. Epub 2022 Aug 22. Vaccine. 2022. PMID: 36031500 Free PMC article.
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population.
Pinpathomrat N, Intapiboon P, Seepathomnarong P, Ongarj J, Sophonmanee R, Hengprakop J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, Sawaengdee W, Phumiamorn S, Sapsutthipas S, Kongkamol C, Ingviya T, Sangsupawanich P, Chusri S. Pinpathomrat N, et al. NPJ Vaccines. 2022 May 13;7(1):52. doi: 10.1038/s41541-022-00475-z. NPJ Vaccines. 2022. PMID: 35562372 Free PMC article.
Comparison of health-oriented cross-regional allocation strategies for the COVID-19 vaccine: a mathematical modelling study.
Yang T, Deng W, Liu Y, Deng J. Yang T, et al. Ann Med. 2022 Dec;54(1):941-952. doi: 10.1080/07853890.2022.2060522. Ann Med. 2022. PMID: 35393922 Free PMC article.

See all "Cited by" articles

References

1. Ahmed S.F., Quadeer A.A., McKay M.R. Preliminary identification of potential vaccine targets for the COVID-19 oronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:E254. doi: 10.3390/v12030254. - DOI - PMC - PubMed
1. Yuen K.S., Ye Z.W., Fung S.Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. doi: 10.1186/s13578-020-00404-4. - DOI - PMC - PubMed
1. Ndaya-Oloo P., Pitisuttithum P., Tornieporth N.G. Vaccine update: recent progress with novel vaccines, and new approaches to safety monitoring and vaccine shortage. J Clin Pharmacol. 2018;58(Suppl 10):S123–S139. doi: 10.1002/jcph.1140. - DOI - PubMed
1. Newton P.N., Timmermann B. Fake penicillin, The Third Man, and Operation Claptrap. BMJ. 2016;355:i6494. doi: 10.1136/bmj.i6494. - DOI - PubMed
1. Tanne J.H. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi: 10.1136/bmj.m1256. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Ahmed S.F., Quadeer A.A., McKay M.R. Preliminary identification of potential vaccine targets for the COVID-19 oronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:E254. doi: 10.3390/v12030254. - DOI - PMC - PubMed

[2] Ahmed S.F., Quadeer A.A., McKay M.R. Preliminary identification of potential vaccine targets for the COVID-19 oronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12:E254. doi: 10.3390/v12030254. - DOI - PMC - PubMed

[3] Yuen K.S., Ye Z.W., Fung S.Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. doi: 10.1186/s13578-020-00404-4. - DOI - PMC - PubMed

[4] Yuen K.S., Ye Z.W., Fung S.Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. doi: 10.1186/s13578-020-00404-4. - DOI - PMC - PubMed

[5] Ndaya-Oloo P., Pitisuttithum P., Tornieporth N.G. Vaccine update: recent progress with novel vaccines, and new approaches to safety monitoring and vaccine shortage. J Clin Pharmacol. 2018;58(Suppl 10):S123–S139. doi: 10.1002/jcph.1140. - DOI - PubMed

[6] Ndaya-Oloo P., Pitisuttithum P., Tornieporth N.G. Vaccine update: recent progress with novel vaccines, and new approaches to safety monitoring and vaccine shortage. J Clin Pharmacol. 2018;58(Suppl 10):S123–S139. doi: 10.1002/jcph.1140. - DOI - PubMed

[7] Newton P.N., Timmermann B. Fake penicillin, The Third Man, and Operation Claptrap. BMJ. 2016;355:i6494. doi: 10.1136/bmj.i6494. - DOI - PubMed

[8] Newton P.N., Timmermann B. Fake penicillin, The Third Man, and Operation Claptrap. BMJ. 2016;355:i6494. doi: 10.1136/bmj.i6494. - DOI - PubMed

[9] Tanne J.H. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi: 10.1136/bmj.m1256. - DOI - PubMed

[10] Tanne J.H. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi: 10.1136/bmj.m1256. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

Affiliation

Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

Author

Affiliation

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous